Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649896 | Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day | PHASE1 | COMPLETED | 76 | — | — | Aug 1, 2003 | Sep 1, 2003 | Apr 1, 2008 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Mylan Estradiol Transdermal System 0.025 mg/day |
| 2 | ACTIVE_COMPARATOR | Climara® Transdermal System 0.025 mg/day |
| Name | Type | Description |
|---|---|---|
| Mylan Estradiol Transdermal System 0.025 mg/day | DRUG | - |
| Climara® Transdermal System 0.025 mg/day | DRUG | - |
Inclusion Criteria: 1. Age: 40-69 years. 2. Sex: Females only. 3. Weight: At least 52 kg (115 lbs) and within 30% of Ideal Body Weight (IBW), as referenced by the Table of "Desirable Weights of Adults" from Metropolitan Life Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN BIOA...